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Abstract: This review examines the use of zoledronic acid in the treatment of Paget’s disease 
of bone. It begins with a brief discussion of the theories of pathogenesis of Paget’s disease, its 
clinical manifestations, and the history of bisphosphonate treatment in this disorder. Risk of 
oversuppression of bone by the more potent bisphosphonates and their association with avascular 
necrosis of the jaw are noted.
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The treatment of Paget’s disease of bone has evolved remarkably over the last several 
decades, from using drugs simply to ease bone pain to using others designed to induce 
remission and prevent deformity. The development of potent bisphosphonates, analogs 
of naturally occurring pyrophosphates, has been responsible for this evolution, and in 
turn has driven our understanding of basic physiology of bone. This review will focus 
on the role of zoledronic acid (Zometa®; Novartis) in the treatment of Paget’s disease. 
The potency and efﬁ  cacy of zoledronic acid in Paget’s disease will be considered in 
the context of the older bisphosphonates, the use of these drugs in other bone diseases, 
and the emerging data on bisphosphonates and skeletal health.
Paget’s disease is thought to be a primary disorder of the osteoclast. The evi-
dence for this is that the earliest radiographic lesion is osteolytic, and that there are 
abnormal numbers of osteoclasts in pagetic bone with an atypical phenotype (Mills 
et al 1980; Kukita et al 1990; Demulder et al 1993). The finding of intranuclear 
inclusions in the pagetic osteoclasts that were characteristic of paramyxoviruses 
(Rebel et al 1981), and the epidemiological work of Khan et al (1996) suggest-
ing Paget’s disease was more common in dog owners, led investigators to seek a 
viral etiology to this disease. Evidence accrued for infection of the osteoclast by 
measles virus or canine distemper virus in patients with Paget’s disease of bone, 
with variable seeding of the osteoclasts in bone accounting for the distribution of 
the pagetic lesions in a given individual. This theory faltered as genetic probing 
of bone cells for evidence of transcripts of these viruses led to conflicting results 
(Mee 1999; Rima et al 2002; Ralston et al 2007). In 2002, Hocking et al (2002) 
identified a mutation in a Canadian cohort in the ubiquitin-binding sequence 
of the sequestosome gene, SQSTM1, occurring in 46% of patients with familial 
Paget’s disease, and in 16% of patients with sporadic Paget’s disease. The muta-
tion affects a scaffolding protein p62 that is involved in osteoclast signaling, and 
that is presumed to enhance osteoclast activation and differentiation (Duran et 
al 2004). By itself, the mutation is insufficient to cause Paget’s disease of bone, 
and environmental factors extrinsic to the osteoclast are being sought to explain 
the variable expression of this disease.Therapeutics and Clinical Risk Management 2007:3(5) 914
Seton and Krane
Paget’s disease is a focal disorder of bone metabolism, 
characterized by an initial phase of bone resorption that 
begins in subchondral bone and moves through the affected 
bone. The bone thickens with the deposition of woven bone 
admixed with lamellar bone, and the marrow is replaced by 
peritrabecular ﬁ  brosis associated with capillary ingrowth. 
The complications of Paget’s disease stem from this bony 
overgrowth, and include deformity, bone pain, fracture, nerve 
compression syndromes and orthopaedic complications (Siris 
and Roodman 2003). In Paget’s disease, the rate of osteoclast 
resorption of bone remains coupled to bone formation, and it 
is sufﬁ  cient to treat the osteoclast to restore bone-remodeling 
rates more towards normal. Currently, all agents used to 
treat Paget’s disease are antiresorptive in nature. Accepted 
therapies today include calcitonin, etidronate, tiludronate, 
clodronate and the newer aminobisphosphonates. This review 
will focus on zoledronic acid, a potent aminobisphosphonate 
just approved in the US for the treatment of Paget’s disease 
of bone (April 2007). Some comments will be made about 
the other bisphosphonates to understand the context in which 
this drug was developed. The ultimate goal of treatment is to 
ease suffering, to prevent the complications of Paget’s disease 
that result from the abnormal resorption and overgrowth of 
bone, and to restore normal bone turnover.
The bisphosphonates are analogs of inorganic pyro-
phosphate, a ubiquitous metabolite in all tissues. The 
bisphosphonates were initially shown to bind to the surface 
of calcium/phosphate mineral phases and impair crystal 
growth as well as dissolution, and were considered for vari-
ous industrial applications based on their physicochemical 
properties. In 1968, Dr Fleisch and colleagues showed that 
bisphosphonates also had the biological property to inhibit 
osteoclastic bone resorption (Fleisch 2002). The drugs bind 
avidly to the calcium/phosphate inorganic mineral phase of 
bone, are not hydrolyzed by pyrophosphatases such as bone 
alkaline phosphatase, and have a sustained effect on bone 
resorption indices. The drugs began to be used in clinical 
medicine, based on these biological properties, for the treat-
ment of Paget’s disease, osteoporosis, hypercalcemia of 
malignancy and complications of bone metastases.
Etidronate, the ﬁ  rst bisphosphonate approved for the 
treatment of Paget’s disease, was noted early on to impair 
mineralization at doses needed to inhibit resorption. Even at 
low therapeutic doses (5 mg/kg), etidronate was associated 
with an increased risk of fracture, bone pain and incomplete 
biochemical response as measured by the percent reduction 
in serum alkaline phosphatase and urinary markers of bone 
resorption (Krane 1982; Evans et al 1983; Hughes et al 1995). 
More potent bisphosphonates were developed that were anti-
resorptive at doses that would not result in bone mineraliza-
tion defects (osteomalacia). The aminobisphosphonates were 
introduced for this reason, and as a class were remarkably well 
tolerated and efﬁ  cacious in the treatment of Paget’s disease.
The aminobisphosphonates include pamidronate, alen-
dronate, risedronate, olpadronate, ibandronate and zole-
dronate. These drugs work by a mechanism distinct from 
etidronate. Speciﬁ  cally, the aminobisphosphonates inhibit 
farnesyl diphosphate synthase, an enzyme in the mevalon-
ate pathway critical in the prenylation of small G-proteins 
that mediate cytoskeletal rearrangement in osteoclasts 
(Widler et al 2002). In 1994, pamidronate was approved 
by the FDA in the US for intravenous treatment of Paget’s 
disease, followed by oral alendronate in 1995, and then oral 
risedronate. Pamidronate, at a therapeutic dose of 30–90 mg, 
required a prolonged infusion time of 2–6 hours. As experi-
ence with the drug grew, and higher doses were used over 
shorter infusion times, collapsing focal glomerulosclerosis 
was observed (Markowitz et al 2003), as well as clinically 
unsuspected osteomalacia (Adamson et al 1993). Further, in 
the years following a larger experience with its use, resistance 
to its pharmacological effects was encountered; this was 
described as a failure to reduce the levels of serum alkaline 
phosphatase by 50%–75% (Trombetti et al 1999; Rendina 
et al 2004). Other complications of the aminobisphospho-
nates were also identiﬁ  ed such as transient ﬂ  u-like symptoms 
with the initial infusion, hypocalcemia (Rosen and Brown 
2003), and rarely iritis (Macarol and Fraunfelder 1994), or 
an allergic reaction.
The bisphosphonates as a class have poor oral availabil-
ity. Zoledronic acid was developed as an intravenous drug 
that could be infused for a brief period in an ambulatory 
setting. Preclinical studies suggested that zoledronate was 
100–850 times more potent than pamidronate in vitro and in 
vivo test systems, and could be administered intravenously 
in effective doses in 15–30 minutes (Body 1997). Preclini-
cal trials suggested that zoledronic acid was also safer than 
pamidronate in terms of renal toxicity, and more effective 
in suppressing bone resorption for a sustained period (Green 
et al 1994, 1997). Using the intravenous route by-passed 
the issues of oral availability and gastrointestinal irritation 
reported with the other potent oral aminobisphosphonates 
alendronate and risedronate, and ensured rapid, easy delivery 
to bone. This regimen offered patients with Paget’s disease, 
as well as those suffering from lytic bone metastases and 
osteoporosis, an opportunity to receive treatment quickly, 
and theoretically, less frequently.Therapeutics and Clinical Risk Management 2007:3(5) 915
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The goal of all treatment with the aminobisphosphonates 
in patients with Paget’s disease of bone is to provide a sus-
tained biochemical remission in disease, and to ease suffering 
caused by skeletal complications of disease. These goals were 
being achieved in many patients with the oral bisphospho-
nates alendronate and risedronate (Siris et al 1996; Brown 
et al 1999; Reid and Siris 1999) when the ﬁ  rst human trials 
with zoledronic acid in humans with Paget’s disease were 
published in 1997 (Arden-Cordone et al 1997). Zoledronic 
acid was infused in 60 mL normal saline over 60 minutes. 
The doses of zoledronic acid tested were 24, 72, 216, and 
400 µg and responses were measured as percentage reduction 
from baseline of calcium/creatinine ratio and 24-hour urinary 
hydroxyproline excretion at 24 hours and at days 3, 7, 10, 
and 24. No signiﬁ  cant changes in these bone markers were 
observed at the lowest doses of zoledronic acid, but at 216 
µg and 400 µg zoledronate, a signiﬁ  cant reduction in urinary 
calcium/creatinine ratio and hydroxyproline excretion were 
noted. No adverse effects such as fever or renal dysfunction 
were seen using this protocol.
In 1999, a dose- ranging study of single doses of zole-
dronic acid was reported (Buckler et al 1999). The primary 
measures of efﬁ  cacy were maximum percent reduction in 
serum alkaline phosphatase and urinary hydroxyproline 
over 3 months in patients with Paget’s disease. One hundred 
seventy-six patients were enrolled, with baseline serum alka-
line phosphatases at least twice the upper limits of normal. 
A therapeutic response was deﬁ  ned as a 50% reduction in 
serum alkaline phosphatase from baseline or normaliza-
tion following treatment. With 400 µg, a 50% decrease 
from baseline serum alkaline phosphatase was seen in 46% 
patients, and normalization in 20%; this dose was far superior 
to 50 µg, 100 µg, 200 µg, and placebo. Side effects such as 
fever, skeletal pain, and asymptomatic hypocalcemia were 
dose related, and transient.
Over the next few years, there were case reports of 
the efﬁ  cacy of zoledronic acid in the treatment of Paget’s 
disease that had proven refractory to other agents (Chung 
and Keen 2003); and the drug was being used at doses of 
4 mg i.v. monthly in patients with cancer metastatic to bone 
(Derenne et al 1999; Rosen et al 2001). Zoledronic acid 
was also being evaluated in clinical trials in patients with 
osteoporosis using 4 mg once yearly (Reid et al 2002), and 
there was ongoing research on the anti-angiogenic properties 
of zoledronic acid in cancer (Fournier et al 2002; Bezzi et al 
2003). During these years as well, the ﬁ  rst reports of acute 
renal failure in patients receiving zoledronate were being 
published (Chang et al 2003; Markowitz et al 2003).
In 2005, Reid and colleagues published the pivotal 
double-blinded, randomized clinical trial using zoledronic 
acid compared to risedronate in patients with Paget’s disease 
(Reid et al 2005). The study design combined two identical, 
double-blinded, randomized controlled trials, comparing 
zoledronic acid with risedronate. It was a 6-month trial, 
with patients either receiving one i.v. infusion of zoledronic 
acid 5 mg (177 patients) or risedronate 30 mg daily for 2 
months (172 patients). Patients were well matched for age, 
elevation in serum alkaline phosphatase, and prior exposure 
to other forms of therapy. All had baseline serum alkaline 
phosphatase more than twice the upper limits of normal; 
patients with evidence of renal disease were excluded (serum 
CrCl 30 mL/min). Adherence to the protocol was better 
than 90%.
The primary end-point was normalization of the serum 
alkaline phosphatase level, or a reduction by 75% in 6 months. 
A pain scale, gait, and quality of life measures were assessed 
as well. At the completion of this study, a greater number 
of patients treated with zoledronic acid (96%) achieved this 
primary end-point compared to those treated with risedro-
nate (74%, p  0.001). Further, zoledronic acid provided 
patients with a signiﬁ  cantly shorter median time to ﬁ  rst 
therapeutic response (64 vs 89 days, p  0.001). In patients 
with Paget’s disease of bone, normalization of serum alkaline 
phosphatase correlates with a longer duration of biochemical 
remission. More patients in the zoledronic acid-treated group 
normalized their serum alkaline phosphatase (88.6%) than 
in the risedronate-treated group (57.9%), p  0.001. Bone 
turnover markers, including serum N-terminal propeptide of 
Type I collagen and serum βC-telopeptide of Type I collagen 
measuring osteoblast function (bone formation), and urinary 
αC-telopeptide of Type I collagen measuring osteoclast func-
tion (bone resorption) were all suppressed into the normal 
range earlier and more consistently in patients treated with 
zoledronic acid, p  0.001.
Clearly, patients had a dramatic biochemical response to 
treatment with zoledronic acid, with many patients having 
suppression of serum alkaline phosphatase into the normal 
range, and a sustained period of biochemical remission. At 
a median of 190 days following the formal trial, only 1 of 
113 patients on zoledronic acid (0.9%) showed evidence of 
recurrent disease activity by biochemical markers, compared 
with 21 of 82 patients on risedronate (25.6%), p  0.001. 
Except for transient fever and ﬂ  u-like symptoms, zoledronic 
acid infusion was well tolerated. Eight patients in all devel-
oped hypocalcemia, severe only in one risedronate-treated 
patient. The mean serum creatinine “decreased slightly but Therapeutics and Clinical Risk Management 2007:3(5) 916
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signiﬁ  cantly by day 10” in patients receiving zoledronic acid 
(p  0.001), but at subsequent visits the values were noted 
to be similar in both treatment groups. Although the study 
was designed to demonstrate the non-inferiority of zoledronic 
acid compared with risedronate in the treatment of Paget’s 
disease, the authors concluded that “zoledronic acid appeared 
to be superior in terms of the degree of disease suppression, 
the rate of onset of effect and (on the basis of preliminary 
data) the persistence of these effects beyond the six-month 
trial period”. In addition, there was a trend towards improved 
quality of life in patients treated with zoledronate.
In a follow-up extension trial of this preliminary study 
published by Hosking and colleagues in 2007, 152 patients 
who had been treated with zoledronic acid and 115 patients 
who had been treated with risedronate were followed for 
18 months to determine the length of remission and durabil-
ity of bone suppression (Hosking et al 2007). Patients were 
eligible for the extension trial if they were in biochemical 
remission, which was deﬁ  ned as normalization or 75% 
reduction of the serum alkaline phosphatase level. The 
extension period was deﬁ  ned as beginning after 6 months 
of therapy, and patients were well matched for age, prior 
history of bisphosphonate use, and biomarkers. A sustained 
therapeutic response was noted in 98% of those treated with 
zoledronic acid vs 57% of those treated with risedronate. 
In the discussion, the authors noted that “a reduction in the 
incidence and severity of long-term complications such as 
fracture and deformity may require persistent normaliza-
tion of bone turnover over many years,” a goal that may be 
achievable with zoledronic acid. In looking at determinants 
of relapse, it was noted that patients treated with risedronate 
who had experienced prior bisphosphonate therapy seemed 
more vulnerable to relapse than those who were treatment 
naïve (p  0.01); this trend was not seen in those treated 
with zoledronate.
Is a very potent bisphosphonate such as zoledronic acid 
really better for patients with Paget’s disease, better for 
an aging skeleton in general, and better in terms of safety 
proﬁ  le? These questions are somewhat difﬁ  cult to answer, 
since it has yet to be determined whether oversuppression of 
bone turnover is a signiﬁ  cant and evolving risk. Citing the 
pivotal trial in the N Engl J Med comparing zoledronic acid 
with risedronate in the treatment of Paget’s disease of bone, 
Hosking et al wrote that “(zoledronic acid) restores normal 
bone turnover in the majority of patients with very active 
Paget’s disease” (Hosking et al 2007). It is a conclusion that 
is largely supported by sustained reductions in bone turnover 
markers and serum alkaline phosphatase, rather than bone 
histomorphometric measurements. We have very little bone 
biopsy data for review. What was available showed “that 
the extent of the mineralizing surface was below the refer-
ence range in the zoledronic acid group (p = 0.04) for the 
comparison with the risedronate group)” (Reid et al 2005). 
Dr Ott, in correspondence published in the N Engl J Med, 
voiced concerns about the consequences of oversuppression 
of bone turnover from bisphosphonates (Ott 2004). In 2003, 
a case report of bisphosphonate-induced osteopetrosis was 
published (Whyte et al 2003), and the ﬁ  rst cases of osteone-
crosis of the jaw were described in association with the use 
of pamidronate and zoledronic acid in patients with bone 
metastases (Marx 2003). None were reported in the two 
studies of zoledronic acid reviewed here. Supporting the 
safety of zoledronic acid used in the treatment of Paget’s 
disease of bone is a recent study looking at comparable 
dosing of zoledronate vs alendronate in a cohort of patients 
with osteoporosis. There was no oversuppression of bone 
formation and no impaired mineralization reported in the 23 
bone biopsies obtained (McClung et al 2007).
Bisphosphonates are now approved for Paget’s disease 
of bone, post-menopausal osteoporosis, postmenopausal 
osteopenia, glucocorticoid-induced osteoporosis in men 
and pre- and post-menopausal women, and metastatic bone 
disease. The consequences of the extension of indications 
to pre-menopausal women and the use in children with 
metabolic bone diseases have not been extensively stud-
ied, although recent reports suggest that these are areas of 
concern in terms of over suppression of bone in vulnerable 
populations. Odvina et al reported severe suppression of 
bone-turnover in fracture patients treated with long-term 
alendronate therapy (Odvina et al 2005). There are increas-
ing numbers of case reports describing “osteonecrosis” of 
the jaw in older cancer patients, particularly those treated 
with monthly intravenous zoledronic acid or pamidronate 
(Maerevoet et al 2005; Marx et al 2005; Merigo et al 2005). 
All of the studies cited reﬂ  ect small cohorts; but because of 
the prolonged retention of bisphosphonates in human bone, 
these observations are troubling. Against these reports are 
insights into the beneﬁ  ts of zoledronic acid in cancer treat-
ment (Daubine et al 2007; Marten et al 2007), and in easing 
the pain of metastatic bone disease (Gralow and Tripathy 
2007); in fracture prevention in patients with osteoporosis 
(Black et al 2007); and in fracture healing (Amanat et al 
2007). In a recent study examining annual zoledronic acid 
therapy in a cohort of 3889 post-menopausal women, Black 
and colleagues reported important reductions in vertebral, 
hip, and other fractures without serious toxicity other than Therapeutics and Clinical Risk Management 2007:3(5) 917
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atrial ﬁ  brillation. Speciﬁ  cally, there were no cases of osteo-
necrosis of the jaw (Black et al 2007). In fact, overall toxicity 
from zoledronic acid seems mostly predictable in the limited 
doses used in patients with Paget’s disease of bone, and most 
side effects can probably be avoided by ensuring adequate 
amounts of vitamin D and calcium are given as supplements 
prior to therapy, renal function is adequate, and good dental 
care is obtained prior to treatment (Lipton 2007).
Theoretically, patients most susceptible to oversup-
pression of bone turnover include dialysis and transplant 
patients at risk for adynamic bone disease; children in whom 
normal post-translational modiﬁ  cation of small G proteins 
is essential for normal growth; pre-menopausal women who 
may yet choose to conceive; and cancer patients undergoing 
dental extractions. Patients with Paget’s disease of bone are 
less vulnerable for many reasons. They tend to be older at 
the time of diagnosis, treatment is limited, and exposure to 
prior bisphosphonate therapy may be minimal. In patients 
with polyostotic Paget’s disease who may have multiple 
co-morbidities, are consuming many oral medications and 
require assistance in transportation to the hospital, a single 
dose of zoledronic acid for the treatment of Paget’s disease 
may ease pain, improve quality of life and facilitate manage-
ment. For younger persons, more likely to have monostotic 
disease, we think any of the newer generation aminobisphos-
phonates constitute adequate treatment, including alendro-
nate and risedronate. These oral aminobisphosphonates 
remain good therapeutic agents in Paget’s disease, and have 
been shown to improve radiographic outcomes, and sup-
press biochemical markers of active Paget’s disease in many 
(Miller et al 1999; Reid and Siris 1999), and they may have 
the advantage of limiting skeletal exposure to bisphospho-
nates. This is unproven. In a recent study published on drug 
utilization of the bisphosphonates in Paget’s disease of bone, 
inappropriate dosing regimens were quite prevalent with the 
oral bisphosphonates, suggesting patients may beneﬁ  t from 
the single dose therapy offered by zoledronate treatment 
(Dolgitser et al 2007).
There are good data indicating that the skeletal extent of 
Paget’s disease is diminishing as an inverse correlate with 
date of birth in the 20th century (Cooper et al 1999; Cundy 
et al 1999; Morales-Piga et al 2002; van Staa et al 2002). 
Even in patients with biochemical remission, abnormal bone 
is still evident in plain radiographs, deformities persist, hear-
ing is not restored and bone is still abnormally vulnerable to 
fracture. Although the premise that early treatment of Paget’s 
disease prevents future complications has a sound theoretical 
basis, there has been no published study proving this to be 
true. Given the changing epidemiology of Paget’s disease 
and the economic incentives at hand, it is unlikely that such 
a study will be undertaken. It seems prudent, therefore, to 
consider the different properties of the aminobisphospho-
nates, the burden of pagetic bone in the skeleton and the 
particular circumstances of a patient when selecting a drug 
for the treatment of Paget’s disease.
In summary, the aminobisphosphonates, prescribed 
thoughtfully, are generally safe and well tolerated, and 
provide a means for treatment of Paget’s disease, metastatic 
cancer of bone, osteoporosis, and other less common disor-
ders such as osteogenesis imperfecta. In the case of Paget’s 
disease of bone, zoledronic acid may be efﬁ  cacious when 
other aminobisphosphonates are not, and may be particularly 
useful in the elderly and in those with polyostotic disease. 
Complications such as osteonecrosis of the jaw are exceed-
ingly rare in patients with Paget’s disease of bone treated 
with a bisphosphonate. It is prudent to recommend that dental 
procedures such as extractions or implants be carried out well 
before treating patients with these more potent bisphospho-
nates, until more is known about the predilection of the jaw 
for osteonecrosis and the basic pathophysiology. Finally, 
supplements of vitamin D and calcium should be given to all 
patients with Paget’s disease treated with bisphosphonates.
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